Today, a Director at Vivus (VVUS), Eric W. Roberts, bought shares of VVUS for $40.97K.
This recent transaction increases Eric W. Roberts’ holding in the company by 104.17% to a total of $79.14K. This is Roberts’ first transaction since reporting a Buy transaction on IVTY back in June 2018
See today’s analyst top recommended stocks >>
Based on Vivus’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $20.11 million and GAAP net loss of $4.5 million. In comparison, last year the company earned revenue of $11.94 million and had a GAAP net loss of $10.08 million. Currently, Vivus has an average volume of 215.3K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A. Palace in April 16, 1991 and is headquartered in Mountain View, CA.
